MX369567B - ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT. - Google Patents
ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT.Info
- Publication number
- MX369567B MX369567B MX2018004348A MX2018004348A MX369567B MX 369567 B MX369567 B MX 369567B MX 2018004348 A MX2018004348 A MX 2018004348A MX 2018004348 A MX2018004348 A MX 2018004348A MX 369567 B MX369567 B MX 369567B
- Authority
- MX
- Mexico
- Prior art keywords
- roryt
- modulators
- syndrome
- disorder
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención comprende compuestos de la Fórmula I: (ver Fórmula) en donde:X, A1, A2, A3, A4, R1, R2 y R3se definen en la especificación; la invención comprende, además, un método para tratar o mejorar un síndrome, un trastorno o una enfermedad, en donde el síndrome, el trastorno o la enfermedad son artritis reumatoide o soriasis;Ia invención comprende, además, un método para modular la actividad de ROR?t en un mamífero por medio de la administración de una cantidad terapéuticamente eficaz de al menos un compuesto de acuerdo con la reivindicación 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462072563P | 2014-10-30 | 2014-10-30 | |
| PCT/US2015/058193 WO2016069974A1 (en) | 2014-10-30 | 2015-10-30 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX369567B true MX369567B (es) | 2019-11-12 |
Family
ID=54754732
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004348A MX369567B (es) | 2014-10-30 | 2015-10-30 | ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT. |
| MX2017005689A MX367912B (es) | 2014-10-30 | 2015-10-30 | ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017005689A MX367912B (es) | 2014-10-30 | 2015-10-30 | ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT. |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US9850236B2 (es) |
| EP (2) | EP3354651B1 (es) |
| JP (3) | JP6998204B2 (es) |
| KR (2) | KR20170127580A (es) |
| CN (3) | CN107827841A (es) |
| AR (2) | AR102480A1 (es) |
| AU (2) | AU2015339087B2 (es) |
| BR (2) | BR112017008816A2 (es) |
| CA (1) | CA2965512C (es) |
| CL (3) | CL2017001042A1 (es) |
| CO (1) | CO2017005014A2 (es) |
| CR (2) | CR20170542A (es) |
| CY (1) | CY1121716T1 (es) |
| DK (1) | DK3212643T3 (es) |
| EA (2) | EA035998B1 (es) |
| EC (1) | ECSP17033054A (es) |
| ES (2) | ES2724556T3 (es) |
| GT (1) | GT201700090A (es) |
| HK (1) | HK1258212A1 (es) |
| HR (1) | HRP20190900T1 (es) |
| HU (1) | HUE043624T2 (es) |
| IL (2) | IL251865A0 (es) |
| JO (2) | JOP20200117A1 (es) |
| LT (1) | LT3212643T (es) |
| MA (1) | MA40873B1 (es) |
| ME (1) | ME03426B (es) |
| MX (2) | MX369567B (es) |
| PE (2) | PE20171649A1 (es) |
| PH (2) | PH12017500800A1 (es) |
| PL (1) | PL3212643T3 (es) |
| PT (1) | PT3212643T (es) |
| RS (1) | RS58613B1 (es) |
| SG (2) | SG11201703323PA (es) |
| SI (1) | SI3212643T1 (es) |
| SV (1) | SV2017005429A (es) |
| TR (1) | TR201907763T4 (es) |
| TW (2) | TWI667230B (es) |
| UY (2) | UY36377A (es) |
| WO (1) | WO2016069974A1 (es) |
| ZA (3) | ZA201703679B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201803869A (zh) * | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑 |
| CN112292124A (zh) * | 2018-03-12 | 2021-01-29 | 爱思凯利尔生物科学私人有限责任公司 | 双环ROR-γ调节剂 |
| KR20210060367A (ko) | 2018-03-12 | 2021-05-26 | 에스칼리에 바이오사이언시스, 비브이 | 스피로사이클릭 ror-감마 조절제 |
| JP2021528398A (ja) | 2018-06-18 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγＴのモジュレーターとしての６−アミノピリジン−３−イルピラゾール |
| CA3103932A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Pyridinyl pyrazoles as modulators of roryt |
| CA3103770A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Phenyl and pyridinyl substituted imidazoles as modulators of roryt |
| WO2019243999A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Phenyl substituted pyrazoles as modulators of roryt |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
| WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL91418A (en) | 1988-09-01 | 1997-11-20 | Rhone Poulenc Agrochimie | (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them |
| JPH10504542A (ja) | 1994-07-27 | 1998-05-06 | ジー．ディー．サール アンド カンパニー | 炎症処置用の置換チアゾール化合物 |
| BR0208956A (pt) | 2001-04-16 | 2004-07-13 | Tanabe Seiyaku Co | Abridor de canais de k ativados por cálcio de grande condutância |
| PL210475B1 (pl) | 2001-08-13 | 2012-01-31 | Janssen Pharmaceutica Nv | Pochodna 2,4,5-tripodstawionego tiazolilu, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania |
| SA04250288B1 (ar) * | 2003-09-19 | 2008-07-19 | سولفاي فارماسوتيكالز بي . في | مشتقات ثيازول thiazole كمعدلات لمستقبل المكونات الكيميائية للقنب cannabinoid |
| WO2006124687A1 (en) | 2005-05-12 | 2006-11-23 | University Of Medicine And Dentistry Of New Jersey | Opioid receptor subtype-selective agents |
| GB0518237D0 (en) * | 2005-09-07 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| AU2007208225B2 (en) | 2006-01-25 | 2013-05-02 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
| WO2008064317A1 (en) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Lipophilic opioid receptor active compounds |
| WO2008064318A2 (en) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Peripheral opioid receptor active compounds |
| US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| AU2009270520A1 (en) | 2008-07-17 | 2010-01-21 | Bayer Cropscience Ag | Heterocyclic compounds used as pesticides |
| TW201040181A (en) * | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| AR079022A1 (es) | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
| EP2368886A1 (en) * | 2010-03-01 | 2011-09-28 | Phenex Pharmaceuticals AG | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease |
| WO2011112264A1 (en) | 2010-03-11 | 2011-09-15 | New York University | Compounds as rorϒt modulators and uses thereof |
| EP3002008B8 (en) | 2010-03-11 | 2018-10-24 | New York University | Amido compounds as roryt modulators and uses thereof |
| WO2011115892A1 (en) | 2010-03-15 | 2011-09-22 | Griffin Patrick R | Modulators of the retinoic acid receptor-related orphan receptors |
| WO2012027965A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| US9505798B2 (en) | 2010-11-29 | 2016-11-29 | New York University | Steroid compounds as RORyt modulators and uses thereof |
| WO2012090995A1 (ja) | 2010-12-28 | 2012-07-05 | ライオン株式会社 | 口腔状態の判定方法、並びにそのために用いられる分析用具、装置、及びプログラム |
| WO2012129491A1 (en) | 2011-03-24 | 2012-09-27 | Abbott Laboratories | Trpv3 modulators |
| US9586928B2 (en) | 2011-05-16 | 2017-03-07 | The Scripps Research Institute | Modulators of the nuclear hormone receptor ROR |
| JP6054869B2 (ja) | 2011-07-29 | 2016-12-27 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2014528933A (ja) | 2011-09-09 | 2014-10-30 | ニューヨーク ユニバーシティ | ＲＯＲγｔモジュレーターとしてのアミド化合物およびその使用 |
| GB201116641D0 (en) * | 2011-09-27 | 2011-11-09 | Glaxo Group Ltd | Novel compounds |
| WO2013079223A1 (en) | 2011-12-02 | 2013-06-06 | Phenex Pharmaceuticals Ag | Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rorϒ, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
| US20130190356A1 (en) | 2011-12-22 | 2013-07-25 | Genentech, Inc. | Benzyl sulfonamide derivatives as rorc modulators |
| SG11201407919WA (en) * | 2012-05-31 | 2014-12-30 | Phenex Pharmaceuticals Ag | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma] |
| JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
| JP6251277B2 (ja) * | 2012-10-16 | 2017-12-20 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲ−ガンマ−ｔのフェニル結合キノリニルモジュレーター |
| US9624210B2 (en) * | 2012-12-12 | 2017-04-18 | Merck Sharp & Dohme Corp. | Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors |
| EP3004081B1 (en) | 2013-06-04 | 2017-11-15 | Acturum Real Estate AB | Triazole compounds and their use as gamma secretase modulators |
| CN103333168B (zh) * | 2013-07-23 | 2015-08-05 | 清华大学 | 一种酰胺类化合物及其制备方法与应用 |
| CN105705501B (zh) | 2013-09-09 | 2019-04-19 | 百时美施贵宝公司 | RORγ调节剂 |
| US20150072890A1 (en) | 2013-09-11 | 2015-03-12 | 20/20 Gene Systems, Inc. | Methods and compositions for aiding in the detection of lung cancer |
| JP6397488B2 (ja) | 2013-09-20 | 2018-09-26 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＲＯＲγ調節因子 |
| JP6320523B2 (ja) * | 2013-10-15 | 2018-05-09 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγＴの第二級アルコールキノリニルモジュレータ |
| CN105873439A (zh) * | 2013-10-15 | 2016-08-17 | 詹森药业有限公司 | RORγt的烷基连接的喹啉基调节剂 |
| PL3077372T3 (pl) | 2013-12-05 | 2019-09-30 | Lead Pharma Holding B.V. | MODULATORY ROR GAMMA (RORγ) |
| US9708253B2 (en) | 2014-01-06 | 2017-07-18 | Bristol-Myers Squibb Company | Cyclohexyl sulfone RORγ modulators |
| TW201609634A (zh) | 2014-01-06 | 2016-03-16 | 必治妥美雅史谷比公司 | 吡咯啶基碸類視色素相關孤兒受體γ（ＲＯＲγ）調節劑 |
| ES2705400T3 (es) | 2014-01-06 | 2019-03-25 | Bristol Myers Squibb Co | Sulfonas heterocíclicas como moduladores de ROR gamma |
| CN106132931B (zh) | 2014-01-06 | 2019-08-02 | 百时美施贵宝公司 | 碳环砜RORγ调节剂 |
| AU2015237788B2 (en) | 2014-03-27 | 2021-03-11 | Piramal Enterprises Limited | ROR-gamma modulators and uses thereof |
| CA2965518A1 (en) | 2014-10-30 | 2016-05-06 | Janssen Pharmaceutica Nv | Amide substituted thiazoles as modulators of ror.gamma.t |
| SI3212641T1 (sl) | 2014-10-30 | 2019-02-28 | Janssen Pharmaceutica Nv | Tiazoli kot modulatorji RORyt |
-
2014
- 2014-10-30 JO JOP/2020/0117A patent/JOP20200117A1/ar unknown
-
2015
- 2015-10-28 TW TW104135342A patent/TWI667230B/zh active
- 2015-10-28 TW TW108110613A patent/TWI705057B/zh active
- 2015-10-29 JO JOP/2015/0267A patent/JO3571B1/ar active
- 2015-10-29 MA MA40873A patent/MA40873B1/fr unknown
- 2015-10-30 PL PL15802227T patent/PL3212643T3/pl unknown
- 2015-10-30 PT PT15802227T patent/PT3212643T/pt unknown
- 2015-10-30 EA EA201891562A patent/EA035998B1/ru not_active IP Right Cessation
- 2015-10-30 WO PCT/US2015/058193 patent/WO2016069974A1/en active Application Filing
- 2015-10-30 US US14/927,499 patent/US9850236B2/en active Active
- 2015-10-30 CN CN201711211144.1A patent/CN107827841A/zh active Pending
- 2015-10-30 UY UY0001036377A patent/UY36377A/es unknown
- 2015-10-30 AR ARP150103522A patent/AR102480A1/es unknown
- 2015-10-30 MX MX2018004348A patent/MX369567B/es unknown
- 2015-10-30 ES ES15802227T patent/ES2724556T3/es active Active
- 2015-10-30 CR CR20170542A patent/CR20170542A/es unknown
- 2015-10-30 ME MEP-2019-118A patent/ME03426B/me unknown
- 2015-10-30 CN CN202110007104.5A patent/CN112979630A/zh active Pending
- 2015-10-30 SG SG11201703323PA patent/SG11201703323PA/en unknown
- 2015-10-30 CN CN201580071983.0A patent/CN107108599A/zh active Pending
- 2015-10-30 HU HUE15802227A patent/HUE043624T2/hu unknown
- 2015-10-30 EA EA201790942A patent/EA033699B1/ru not_active IP Right Cessation
- 2015-10-30 EP EP18160676.5A patent/EP3354651B1/en active Active
- 2015-10-30 LT LTEP15802227.7T patent/LT3212643T/lt unknown
- 2015-10-30 BR BR112017008816A patent/BR112017008816A2/pt not_active Application Discontinuation
- 2015-10-30 ES ES18160676T patent/ES2858503T3/es active Active
- 2015-10-30 EP EP15802227.7A patent/EP3212643B1/en active Active
- 2015-10-30 CA CA2965512A patent/CA2965512C/en active Active
- 2015-10-30 TR TR2019/07763T patent/TR201907763T4/tr unknown
- 2015-10-30 SG SG10201805355YA patent/SG10201805355YA/en unknown
- 2015-10-30 AU AU2015339087A patent/AU2015339087B2/en active Active
- 2015-10-30 PE PE2017000795A patent/PE20171649A1/es unknown
- 2015-10-30 BR BR122017023050A patent/BR122017023050A2/pt not_active Application Discontinuation
- 2015-10-30 KR KR1020177032857A patent/KR20170127580A/ko not_active Application Discontinuation
- 2015-10-30 JP JP2017523358A patent/JP6998204B2/ja active Active
- 2015-10-30 PE PE2017002473A patent/PE20180250A1/es unknown
- 2015-10-30 RS RS20190495A patent/RS58613B1/sr unknown
- 2015-10-30 CR CR20170166A patent/CR20170166A/es unknown
- 2015-10-30 MX MX2017005689A patent/MX367912B/es active IP Right Grant
- 2015-10-30 DK DK15802227.7T patent/DK3212643T3/da active
- 2015-10-30 KR KR1020177014519A patent/KR20170078750A/ko not_active Application Discontinuation
- 2015-10-30 SI SI201530677T patent/SI3212643T1/sl unknown
-
2017
- 2017-04-23 IL IL251865A patent/IL251865A0/en unknown
- 2017-04-27 PH PH12017500800A patent/PH12017500800A1/en unknown
- 2017-04-27 CL CL2017001042A patent/CL2017001042A1/es unknown
- 2017-04-28 SV SV2017005429A patent/SV2017005429A/es unknown
- 2017-04-28 GT GT201700090A patent/GT201700090A/es unknown
- 2017-05-19 CO CONC2017/0005014A patent/CO2017005014A2/es unknown
- 2017-05-29 ZA ZA2017/03679A patent/ZA201703679B/en unknown
- 2017-05-30 EC ECIEPI201733054A patent/ECSP17033054A/es unknown
- 2017-07-31 US US15/664,673 patent/US10150762B2/en active Active
- 2017-11-08 AR ARP170103107A patent/AR110155A2/es unknown
- 2017-11-14 IL IL255648A patent/IL255648B/en active IP Right Grant
- 2017-11-20 PH PH12017502105A patent/PH12017502105A1/en unknown
- 2017-12-14 UY UY0001037517A patent/UY37517A/es unknown
-
2018
- 2018-02-09 HK HK19100569.0A patent/HK1258212A1/zh unknown
- 2018-02-16 CL CL2018000436A patent/CL2018000436A1/es unknown
- 2018-08-31 ZA ZA201805861A patent/ZA201805861B/en unknown
- 2018-08-31 ZA ZA201805860A patent/ZA201805860B/en unknown
- 2018-10-25 JP JP2018200608A patent/JP6623270B2/ja not_active Expired - Fee Related
-
2019
- 2019-01-14 AU AU2019200228A patent/AU2019200228B2/en active Active
- 2019-05-15 HR HRP20190900TT patent/HRP20190900T1/hr unknown
- 2019-06-04 CL CL2019001514A patent/CL2019001514A1/es unknown
- 2019-06-14 CY CY20191100620T patent/CY1121716T1/el unknown
-
2020
- 2020-06-18 JP JP2020104927A patent/JP2020180129A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500800A1 (en) | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | |
| MX358508B (es) | Moduladores de quinolinilo unidos a metileno de receptor nuclear de acido retinoico-gamma-t. | |
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| MX2018013143A (es) | 6-aminopiridin-3-il tiazoles como moduladores de ror?t. | |
| PH12015500776A1 (en) | Phenyl linked quinolinyl modulators of ror-gamma-t | |
| MX2018003472A (es) | Moduladores de la expresion de kras. | |
| MX2016014294A (es) | Composiciones y metodos para modular la expresion del factor b del complemento. | |
| BR112017008852A2 (pt) | tiazóis substituídos com amida como moduladores do roryt | |
| BR112016008258A2 (pt) | moduladores de ror?t de quinolinila | |
| BR112017008842A2 (pt) | tiazóis como moduladores de ror?t | |
| MX2020007369A (es) | Moduladores de la expresion de dnm2. | |
| WO2015057200A8 (en) | Heteroaryl linked quinolinyl modulators of rorϒt | |
| BR112016008257A2 (pt) | moduladores de roryt de álcool quinolínico secundário | |
| BR112016008183A2 (pt) | Moduladores de ror-gama-t de quinolinila ligados à fenila |